Perspective Therapeutics (CATX) said Friday it has dosed the first patient in a new cohort of its phase 1/2a trial evaluating [212Pb]VMT01 as a monotherapy for melanoma patients with confirmed positive MC1R imaging scans.
This cohort includes patients with brain metastases and administers [212Pb]VMT01 at a dose of 1.5 millicuries.
The investigational therapy delivers targeted alpha-particle therapy to treat metastatic melanoma. The US Food and Drug Administration granted Fast Track Designation for [212Pb]VMT01 in September 2024.
Perspective Therapeutics shares were up over 17% in recent premarket activity.
Price: 2.19, Change: +0.33, Percent Change: +17.74
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.